Ciantra Z, Paraskevopoulou V, Aifantis I
Nat Immunol. 2025; 26(3):351-365.
PMID: 40021898
DOI: 10.1038/s41590-025-02096-9.
Naji N, Sathish M, Karantanos T
Cancers (Basel). 2024; 16(23).
PMID: 39682161
PMC: 11640130.
DOI: 10.3390/cancers16233974.
Fang J, Zhang J, Zhu L, Xin X, Hu H
PeerJ. 2024; 12:e18656.
PMID: 39655332
PMC: 11627098.
DOI: 10.7717/peerj.18656.
Orofino G, Vago L
Hematology Am Soc Hematol Educ Program. 2024; 2024(1):736-743.
PMID: 39644002
PMC: 11665623.
DOI: 10.1182/hematology.2024000588.
Rambaldi B, Rizzuto G, Rambaldi A, Introna M
Front Immunol. 2024; 15:1459175.
PMID: 39512351
PMC: 11540647.
DOI: 10.3389/fimmu.2024.1459175.
Inferior Overall Survival After Haploidentical Donor Lymphocyte Infusions in Relapsed Myeloid Neoplasms.
Benoit T, Bachofner A, Wolfensberger N, Zaugg-Berger Y, Manz M, Schneidawind D
Eur J Haematol. 2024; 114(2):315-324.
PMID: 39501442
PMC: 11707813.
DOI: 10.1111/ejh.14340.
Finding potential targets in cell-based immunotherapy for handling the challenges of acute myeloid leukemia.
Kheirkhah A, Habibi S, Yousefi M, Mehri S, Ma B, Saleh M
Front Immunol. 2024; 15:1460437.
PMID: 39411712
PMC: 11474923.
DOI: 10.3389/fimmu.2024.1460437.
Therapeutic targeting of PARP with immunotherapy in acute myeloid leukemia.
Bian X, Liu W, Yang K, Sun C
Front Pharmacol. 2024; 15:1421816.
PMID: 39175540
PMC: 11338796.
DOI: 10.3389/fphar.2024.1421816.
A Difficult Case of Calcineurin Inhibitor Neurotoxicity Post-Haploidentical HCT With a Successful Novel Solution: Cytotoxic T-Lymphocyte-Associated Protein 4-Immunoglobulin Blockade for GVHD Prophylaxis.
Dykes K, Tzachanis D, Koura D
Cell Transplant. 2024; 33:9636897241265249.
PMID: 39076086
PMC: 11289812.
DOI: 10.1177/09636897241265249.
Single-cell immune landscape of measurable residual disease in acute myeloid leukemia.
Mo X, Zhang W, Fu G, Chang Y, Zhang X, Xu L
Sci China Life Sci. 2024; 67(11):2309-2322.
PMID: 39034351
DOI: 10.1007/s11427-024-2666-8.
Oncogene-induced TIM-3 ligand expression dictates susceptibility to anti-TIM-3 therapy in mice.
Talvard-Balland N, Braun L, Dixon K, Zwick M, Engel H, Hartmann A
J Clin Invest. 2024; 134(16).
PMID: 38916965
PMC: 11324309.
DOI: 10.1172/JCI177460.
Continuously improving outcome over time after second allogeneic stem cell transplantation in relapsed acute myeloid leukemia: an EBMT registry analysis of 1540 patients.
Schmalter A, Ngoya M, Galimard J, Bazarbachi A, Finke J, Kroger N
Blood Cancer J. 2024; 14(1):76.
PMID: 38697960
PMC: 11066014.
DOI: 10.1038/s41408-024-01060-4.
Haploidentical transplantation in primary refractory/relapsed secondary vs de novo AML: from the ALWP/EBMT.
Nagler A, Labopin M, Tischer J, Raiola A, Kunadt D, Vydra J
Blood Adv. 2024; 8(15):4223-4233.
PMID: 38598754
PMC: 11372397.
DOI: 10.1182/bloodadvances.2024012798.
GPR56 in GVL: marker or mechanism?.
Iness A, Bachireddy P
Blood. 2024; 143(13):1206-1207.
PMID: 38546637
PMC: 10997899.
DOI: 10.1182/blood.2023023448.
Remission of relapsed/refractory classical Hodgkin lymphoma induced by brentuximab vedotin and pembrolizumab combination after allogeneic hematopoietic stem cell transplantation: a case report.
Giannotti F, de Ramon Ortiz C, Simonetta F, Morin S, Bernardi C, Masouridi-Levrat S
Front Immunol. 2024; 15:1360275.
PMID: 38510239
PMC: 10950903.
DOI: 10.3389/fimmu.2024.1360275.
Metabolic instruction of the graft-versus-leukemia immunity.
Burk A, Apostolova P
Front Immunol. 2024; 15:1347492.
PMID: 38500877
PMC: 10944922.
DOI: 10.3389/fimmu.2024.1347492.
Targeting natural killer cells: from basic biology to clinical application in hematologic malignancies.
Shang J, Hu S, Wang X
Exp Hematol Oncol. 2024; 13(1):21.
PMID: 38396050
PMC: 10885621.
DOI: 10.1186/s40164-024-00481-y.
Proteomics to predict relapse in patients with myelodysplastic neoplasms undergoing allogeneic hematopoietic cell transplantation.
Guru Murthy G, Zhang T, Bolon Y, Spellman S, Dong J, Auer P
Biomark Res. 2024; 12(1):10.
PMID: 38273355
PMC: 10809608.
DOI: 10.1186/s40364-023-00550-0.
Comparison of antibody-based immunotherapeutics for malignant hematological disease in an experimental murine model.
Frebel K, Albring J, Wohlgemuth A, Schwoppe C, Hailfinger S, Lenz G
Blood Adv. 2024; 8(8):1934-1945.
PMID: 38197968
PMC: 11021910.
DOI: 10.1182/bloodadvances.2023011647.
Relapse of acute myeloid leukemia after allogeneic stem cell transplantation: immune escape mechanisms and current implications for therapy.
Sauerer T, Velazquez G, Schmid C
Mol Cancer. 2023; 22(1):180.
PMID: 37951964
PMC: 10640763.
DOI: 10.1186/s12943-023-01889-6.